Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$13.24M$13.24M−0.2% vs Q2 2022 Net Income-$5.79M-$5.79MN/M vs Q2 2022 EPS Diluted-$0.10-$0.10N/M vs Q2 2022 Operating Income-$4,209,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,733,000N/M Margins · derivedOperating margin-31.8%+64.4 pt vs Q2 2022
Net margin-43.7%+79.2 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 7, 2023 · 38 d after period end